The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2-8 October 2022 and includes updates on avian influenza, COVID-19, dengue, Ebola, invasive meningococcal disease, West Nile Virus, MERS-CoV, monkeypox, and hepatitis.
For 2020, 29 EU/EEA Member States reported 14 428 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases (14 137) corresponds to a crude rate of 4.2 cases per 100 000 population.
In 2018, 3 233 confirmed cases of invasive meningococcal disease (IMD), including 324 deaths, were reported in 30 European Union/European Economic Area (EU/EEA) Member States.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.